Evidence mapPaperPMID 33369175Full record

ArticleJournal of diabetes investigation2021

Impact of glucagon response on early postprandial glucose excursions irrespective of residual β-cell function in type 1 diabetes: A cross-sectional study using a mixed meal tolerance test.

Ayako Ito, Ichiro Horie, Masaki Miwa, Ayaka Sako, Tetsuro Niri, Yomi Nakashima, Riyoko Shigeno, Ai Haraguchi, Shoko Natsuda, Satoru Akazawa and 3 more

Open access · goldAbstract read
In one paragraph

Article in Journal of diabetes investigation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Advances in clinical research on glucagon.Diabetology international · 2024
    Review
  7. Article
  8. Article
  9. Effects of Low-Dose Glucagon on Subcutaneous Insulin Absorption in Pigs.Current therapeutic research, clinical and experimental · 2024
    Article
  10. Article
  11. The Role of Glucagon in Glycemic Variability in Type 1 Diabetes: A Narrative Review.Diabetes, metabolic syndrome and obesity : targets and therapy · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Ayako ItoDepartment of Endocrinology and Metabolism, Nagasaki University Hospital, Nagasaki, Japan.ORCID https://orcid.org/0000-0002-0335-933X
Ichiro HorieDepartment of Endocrinology and Metabolism, Nagasaki University Hospital, Nagasaki, Japan.ORCID https://orcid.org/0000-0003-3430-5796
Masaki MiwaCenter of Diabetes Care Medicine, Nagasaki University Hospital, Nagasaki, Japan.
Ayaka SakoDepartment of Endocrinology and Metabolism, Nagasaki University Hospital, Nagasaki, Japan.
Tetsuro NiriDepartment of Endocrinology and Metabolism, Nagasaki University Hospital, Nagasaki, Japan.
Yomi NakashimaDepartment of Endocrinology and Metabolism, Nagasaki University Hospital, Nagasaki, Japan.
Riyoko ShigenoDepartment of Endocrinology and Metabolism, Nagasaki University Hospital, Nagasaki, Japan.
Ai HaraguchiDepartment of Endocrinology and Metabolism, Nagasaki University Hospital, Nagasaki, Japan.
Shoko NatsudaDepartment of Endocrinology and Metabolism, Nagasaki University Hospital, Nagasaki, Japan.
Satoru AkazawaDepartment of Endocrinology and Metabolism, Nagasaki University Hospital, Nagasaki, Japan.
Akie KamadaCenter of Diabetes Care Medicine, Nagasaki University Hospital, Nagasaki, Japan.
Atsushi KawakamiDepartment of Endocrinology and Metabolism, Nagasaki University Hospital, Nagasaki, Japan.
Norio AbiruDepartment of Endocrinology and Metabolism, Nagasaki University Hospital, Nagasaki, Japan.
Nagasaki University Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

AIMS/

introductionControlling postprandial glucose levels in patients with type 1 diabetes is challenging even under the adequate treatment of insulin injection. Recent studies showed that dysregulated glucagon secretion exacerbates hyperglycemia in type 2 diabetes patients, but little is known in type 1 diabetes patients. We investigated whether the glucagon response to a meal ingestion could influence the postprandial glucose excursion in patients with type 1 diabetes. MATERIALS AND

methodsWe enrolled 34 patients with type 1 diabetes and 23 patients with type 2 diabetes as controls. All patients underwent a liquid mixed meal tolerance test. We measured levels of plasma glucose, C-peptide and glucagon at fasting (0 min), and 30, 60 and 120 min after meal ingestion. All type 1 diabetes patients received their usual basal insulin and two-thirds of the necessary dose of the premeal bolus insulin.

resultsThe levels of plasma glucagon were elevated and peaked 30 min after the mixed meal ingestion in both type 1 diabetes and type 2 diabetes patients. The glucagon increments from fasting to each time point (30, 60 and 120 min) in type 1 diabetes patients were comparable to those in type 2 diabetes patients. Among the type 1 diabetes patients, the glucagon response showed no differences between the subgroups based on diabetes duration (<5 vs ≥5 years) and fasting C-peptide levels (<0.10 vs ≥0.10 nmol/L). The changes in plasma glucose from fasting to 30 min were positively correlated with those in glucagon, but not C-peptide, irrespective of diabetes duration and fasting C-peptide levels in patients with type 1 diabetes.

conclusionsThe dysregulated glucagon likely contributes to postprandial hyperglycemia independent of the residual β-cell functions during the progression of type 1 diabetes.

Indexed as

AdultAgedBlood GlucoseCohort StudiesC-PeptideCross-Sectional StudiesDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2FemaleGlucagonGlucose Tolerance TestHumansHyperglycemiaInsulin-Secreting CellsMaleMealsBlood GlucoseC-PeptideGlucagonGlucagonMeal tolerance testType 1 diabetes

Identifiers

PMID33369175
PMCPMC8354509
OpenAlexW3114559895

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.